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Abstract
Caveolae are small, “omega-shaped” invaginations at the plasma membrane of the cell which are involved in a
variety of processes including cholesterol transport, potocytosis and cell signalling. Within caveolae there are
caveolae-associated proteins, and changes in expression of these molecules have been described to play a role in
the pathophysiology of various diseases including cancer and cardiovascular disease. Evidence is beginning to
accumulate that epigenetic processes may regulate the expression of these caveolae related genes, and hence
contribute to disease progression. Here, we summarize the current knowledge of the role of epigenetic modification in
regulating the expression of these caveolae related genes and how this relates to changes in cellular physiology and in
health and disease.
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Introduction
Caveolae are small specialized “cave-like” microdomains at
the plasma membrane that function as trafficking vesicles
and are involved in organization of signal transduction.
Caveolae are present in most tissues and are particularly
abundant in cardiac, continuous endothelial and epithelial
cells, as well as fat cells [1–3]. Within caveolae are caveo-
lae associated proteins; caveolin-1 (CAV1) [4], caveolin-2
(CAV2) [5], caveolin-3 (CAV3) [6], Cavin-1 (also know as
polymerase-1 and transcript release factor) (PTRF) [7],
Cavin-2 [8], Cavin-3 [9] and Cavin-4 [10], which are im-
portant for the formation and maintenance of the caveolar
structure.
CAV1 is a 22 kDa protein which is the principal substrate
of src kinase [11] and appears as a filament-like structure at
the plasma membrane [12]. CAV1 is expressed in a wide
range of tissues with the highest expression in smooth
muscle cells, adipocytes, fibroblasts and endothelial cells
[13]. CAV1 plays an important role in the formation of
caveolae; if cells lack CAV1, no caveolae are observed
[14] while, restoration of CAV1 expression results in
the de novo formation of caveolae [15, 14]. CAV1 knock
out mice demonstrate a variety of physiological defects
including reduced renal calcium reabsorption and vas-
cular and metabolic abnormalities [16–18]. CAV1 is also
reported to be involved in diseases such as cancer, cardio-
vascular disease and diabetes (for review see [19]).
CAV2 is a 20 kDA protein found abundantly in white
adipose tissue [5]. Expression of CAV2 is independent of
caveolae formation, however, co-expression of CAV2 with
CAV1 results in more abundant invaginations and more
uniform caveolae formation [20, 21]. Thus while CAV2
may not be essential, it plays a supporting role in modulat-
ing the biogenesis of caveolae. CAV2 is expressed concur-
rently with CAV1 and can undergo hetro-oligomerization
with CAV1 [22]. In addition, CAV2 has been shown to
interact with CAV3 in cardiac muscle cells [23]. CAV2
knock out mice have normal distribution of caveolae but
display a variety of lung disorders [21].
CAV3 has a molecular weight of 18–20 kDA and is
85 % similar to CAV1 [6]. It is predominantly expressed
in muscle cells [6]. CAV3 co-immunoprecipitates with
dystrophin, suggesting that dystrophin and CAV3 can
exist as a discrete complex [24]. In embryonic fibroblasts
derived from caveolae-null mice, restoration of CAV3
successfully restores the formation of caveolae [25].
CAV3 knock out mice show a loss of caveolae at the
sarcolemma (but not endothelial cells), exclusion of
dystrophin-glycoprotein complexes from the lipid rafts,
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abnormalities of the T-tubule system, insulin resistance
and instability of the insulin receptor in skeletal muscle
[26, 27]. Similarly, analysis of cardiac muscle from CAV1
knock out mice demonstrates a loss of caveolae in the
cardiac endothelial cells but not cardiac myocytes, how-
ever the opposite observation was seen in CAV3 knock
out mice [28]. Only in CAV1 CAV3 double knock out
mice were caveolae completely abolished in both cell
types [28]. This suggests that CAV3 can compensate for
CAV1 allowing caveolae formation in cardiac myocytes,
providing some functional redundancy [28].
PTRF was cloned in 1998 and was first described to be
involved in RNA transcription machinery [29, 30]. PTRF is
a resident protein in caveolae [31] and is widely expressed
in a range of tissues, with highest expression in adipocytes,
cardiac and skeletal muscles and osteoblasts [32]. The func-
tional role of PTRF in caveolae formation has only recently
been described. Loss of PTRF is accompanied by reduced
numbers of caveolae [33, 34]. Re-expression of PTRF in cell
lines that have reduced or lack PTRF results in caveolae
formation [35, 7]. PTRF knock out mice lack caveolae and
demonstrate glucose intolerance and disorders of the lungs
and cardiovascular system [34, 36–39].
Structurally, Cavin-2 is ~ 20 % similar to PTRF [40]. Al-
though down-regulation of Cavin-2 in turn causes reduced
PTRF and CAV1 expression (hence reduced caveolae
number), suggesting the interdependency between these 3
molecules [8], the expression of Cavin-2 alone does not
alter the number of caveolae [40, 41]. However, the ex-
pression of Cavin-2 induces tube-like morphological
changes to caveolae [40]. Cavin-3 is reported to be associ-
ated with CAV1 during caveolae budding [9]. The process
of caveolae budding and trafficking of caveolae-associated
vesicles along the microtubules is greatly impaired in the
absence of Cavin-3, suggesting a role of Cavin-3 in intra-
cellular transport mechanisms [9]. Cavin-4 is only present
in muscle cells and is a cytosolic protein that is able to
interact with Cavin-2. Cavin-4 has been demonstrated to
be important in cardiac dysfunction where Cavin-4 is able
to modulate the Rho/ROCK pathway that is important for
cardiac muscle biogenesis [42].
Changes in the expression of the caveolae related pro-
teins are associated with disease. For example, expression
of CAV1, CAV2 and PTRF is dysregulated in prostate and
breast cancer [33, 43]. Furthermore, other health issues
such as cardiovascular disease, inflammation and abnor-
mal insulin signaling are associated with changes in these
proteins [44, 39]. However, what causes the change in ex-
pression of these caveolae related molecules is unknown.
Potentially, these changes may be related to epigenetic or
micro-RNA (miRNA) mechanisms that act upstream of
the genes. This review brings together the current evi-
dence for epigenetic regulation of these genes and thus,
presence of caveolae. As there are limited data, or no
evidence, published on CAV3, Cavin-2, Cavin-3 and
Cavin-4, this review will focus on CAV1, CAV2 and PTRF.
Review
Evidence for epigenetic changes related to CAV1, CAV2
and PTRF
Epigenetics involves the study of the changes in gene
expression that are independent of any changes in DNA
sequences. There are two main mechanisms under the um-
brella of epigenetics; DNA methylation, which involves the
methylation of the promoter region of the gene and histone
deacetylation which involves structural changes of the chro-
matin. Importantly epigenetic changes can be reversed with
the use of chemical agents [45].
DNA promoter hypermethylation involves the modifica-
tion of cytosine residues in the CpG dinucleotides to form
5-methylcytosine through covalent addition of a methyl
group by the enzyme, DNA methyltransferase. In the mam-
malian genome, CpG dinucleotides are unevenly distributed
to form short sequences that have high densities of CpG di-
nucleotides known as CpG islands (CpGi) [46], within the
promoter region of the genome. Gene promoters which
have their CpGi methylated are transcriptionally in-
active as the methyl groups block the promoter region
from being accessed by transcriptional elements [45].
Chemical agents such as 5-AZA-2′-deoxycytidine (5-AZA)
have been reported to reverse DNA promoter hypermethy-
lation [47–49].
More recent studies suggest that methylation can also
occur in non-CpGi rich areas in the promoter region to
silence gene expression. These regions have a lesser
density of CpGi and are normally situated around 2 kb
from the regular CpGi rich regions, and have been
named CpGi shores [50, 51]. Hypermethylation at the
CpGi shore appears to have a critical role in regulating
gene expression [50]
Allfrey et al. [52] described that for gene expression to
take place, the ε-amino group in the lysine residue of
the histone cores must be acetylated by histone acetyl-
transferases (HATs). Histone deacetylases (HDACs) can-
cel the effect of HATs by removing acetyl groups from
the lysine residue in histone cores. The removal of acetyl
groups by HDACs restores the positive charges on lysine
residues. This causes the histone tails to coil tightly to
the DNA leading to transcriptional inactivation as the
transcriptional machinery is unable to access the DNA
[52, 53]. The use of Trichostatin-A (TSA), a microbial
metabolite capable of inhibiting HDACs, was first de-
scribed in 1995 and has been used to re-express genes
which are inactivated by histone deacetylation [54]. Gene
transcription is restored when lysine residues in the his-
tone tails are acetylated through inactivation of HDACs
by TSA [54].
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To date, most of the reports of epigenetic effects on
CAV1 are related to DNA methylation and in the con-
text of cancer (Table 1). It is suggested that the 5′ pro-
moter of CAV1 is methylated in human breast cancer
cell lines, MDA-MB-231, MCF7 and T-47D but not in
normal human mammary epithelial cells [55, 43]. Studies
of clinical tissues have shown that breast cancer tissues
have hypermethylation of the CAV1 promoter accom-
panied by down-regulation of CAV1 expression when
compared to adjacent normal breast tissues [56, 57].
Furthermore, CAV1 promoter hypermethylation is sig-
nificantly associated with the histopathological grade of
the tumor [56].
Nodal metastasis has been reported to be associated
with CAV1 hypermethylation [58]. It has been suggested
that inactivation of CAV1 through hypermethylation
drives the spread of breast cancer to the lymph nodes
[58]. Treatment of breast cancer cell lines with 5-AZA
successfully increases both CAV1 mRNA and protein
[43, 59]. However, in a subtype of breast cancer, inflam-
matory breast cancer (IBC), CAV1 is reported to be
hypomethylated resulting in overexpression of CAV1
[60]. Therefore it may suggest that different breast can-
cer subtypes may have different changes in epigenetic
regulation of CAV1.
Recent evidence suggests that CpGi shores are involved
in regulation of CAV1 expression. Treatment with a DNA
methyltransferase inhibitor induces expression of CAV1
through demethylation of CpGi shores in breast cancer
cell lines that have low CAV1 expression (even though the
CpGi rich promoters are hypermethylated) [61]. CpGi
shores are reported to be hypermethylated in less ag-
gressive breast cancer cells whereas hypomethylation of
CpGi shores is observed in highly aggressive breast
cancer cells [61].
In prostate cancer CAV1 is down-regulated and this is
accompanied by promoter hypermethylation of CpGi
sites at the 5′ promoter region of CAV1 [62, 63]. Bisul-
fite sequencing suggests promoter hypermethylation
may be a mechanism for down-regulation of CAV1 gene
expression [64]. However, loss of CAV1 expression was
observed in androgen dependent LNCaP cells while in-
creased expression occurred in PC3 cells and tissues
from advanced cancer [33]. Thus, expression of CAV1
may be lost in the early stages of prostate cancer and
promote cancer cell proliferation and survival, but up-
regulated at late stages of prostate cancer to favor
metastasis, inhibit apoptosis and promote multi-drug re-
sistance [65]. A possible explanation for the conditional
role of CAV1 as both tumor promoter and suppressor is
the interaction of CAV1 with other effector molecules
that may directly or indirectly interact with or affect
CAV1’s function [65]. Possible examples are Mgat5 and
galectin-3. In early stages of prostate cancer, the expres-
sion of CAV1 is lost and the expression of Mgat5 and
galectin-3 is at low levels. However, in later stages of
prostate cancer, expression and formation of Mgat5/
galectin-3 lattices may stimulate and elevate the
Table 1 Involvement of CAV1 epigenetic modification in cancers
Cancer types Promoter hypermethylation Histone modification CAV1 expression Changes in physiology and pathophysiology







Prostate [62] Down-regulated Not described
[64]
[63]
Bladder [68] Down-regulated Not described
Ovarian [71] [71] Down-regulated Over-expression of CAV1, reduced colony formation
and increased apoptosis in ovarian cancer cell line [71]
Lung [70] Down-regulated Over-expression of CAV1, reduced colony formation
in lung cancer cell line [70]
Colorectal [72] Down-regulated Not described
[73]
[74]
Liver [75] Down-regulated Not described
[77]
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expression of CAV1 through phosphorylation, resulting
in up-regulated CAV1 expression in advanced prostate
tumours [65–67].
Promoter methylation is also seen in a variety of
other cancers and appears to be cell specific in a given
organ (Table 1). For example, CAV1 promoter methyla-
tion is seen in undifferentiated small cell and squamous
cell carcinoma but not in transitional cell [68] or pri-
mary adenocarcinomas and signet ring cell carcinomas
of the bladder [69]. Similar cell specificity is seen in
lung cancers [70].
Treatment with 5-AZA has been shown to restore
CAV1 expression in some cancers confirming hyperme-
thylation. CAV1 expression is down-regulated in ovarian
cancer cell lines but expression can be restored by treat-
ing the cells with 5-AZA [71]. CAV1 promoter hyperme-
thylation has also been reported in sporadic colorectal
cancer [72] and re-expression of CAV1 was observed in
colon cancer cell lines after 5-AZA treatment [73, 74].
Promoter hypermethylation of CAV1 is also seen in
hepatocellular carcinoma (HCC) cell lines [75] and
HCC tissues and is accompanied by reduced expression
of CAV1 [75]. Further, 5-AZA treatment causes up-
regulated CAV1 expression in hepatoma cells [75]. One
of the risk factors for hepatocellular carcinoma (HCC)
is exposure to Hepatitis B Virus (HBV) and in particu-
lar to HBV’s X protein. This protein is able to promote
tumorigenesis through activation of signaling pathways,
growth factors and oncogenes. Furthermore, HBV’s X
protein inactivates negative growth regulators such as
p53 to favor metastasis [76, 77]. Interestingly, HCC
samples that are infected with HBV show significant
suppression of CAV1 expression through hypermethy-
lation of CAV1’s promoter [77], due to the hypermethy-
lation effect of HBV’s X protein on CAV1’s promoter
(Fig. 1) [77].
Other than promoter hypermethylation, histone modi-
fication has also been reported as a mechanism to si-
lence CAV1 expression. In ovarian cancer cell lines,
treatment with TSA up-regulates CAV1 [71] and in
breast cancer cell lines, TSA treatment results in a 35
fold increase in CAV1 expression [59].
Estrogen receptors alpha (ERα) and beta (ERβ) are
expressed in neuronal cells [78, 79]. Ectopic expression
of ERα in SK-N-MC neuronal cells leads to epigenetic si-
lencing of CAV1 (and down-regulation of CAV1) while
treatment with 5-AZA and TSA results in partial restor-
ation of CAV1 expression. However, when ERβ is co-
expressed with ERα in SK-N-MC cells, the effect on
CAV1 is abolished, suggesting ERβ counteracts the effect
of ERα on CAV1 down-regulation through an epigenetic
pathway (Fig. 2) [80]. However, the exact molecular
mechanism is not well understood and this observation
may be due to a direct ERα targeting effect or indirect
Fig. 1 Effect of HBV’s X protein on CAV1 expression. HCC samples
infected with HBV demonstrate decreased CAV1 expression. This
effect is due to the promoter hypermethylation of CAV1 by HBV’s X
protein, causing transcriptional silencing of CAV1
Fig. 2 The mechanism of action of ER isoforms on CAV1 expression.
Over-expression of ERα leads to down-regulation of CAV1 expression
through epigenetic mechanisms. However, the co-expression of ERβ
inhibits the effect of ERα, resulting in removal of the transcriptional
suppression activity of ERα
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silencing of CAV1 through ectopic expression of ERα. In
neuronal cells that over-express ERα, CAV2 expression
is also down-regulated. 5-AZA treatment results in re-
expression of CAV2, but TSA treatment has no effect
[80]. This suggests that ERα is able to silence CAV2
through DNA promoter methylation but not histone
modification, suggesting another level of regulation.
To date, there are limited data describing the epigen-
etic regulation of PTRF. PTRF is down-regulated in
breast cancer cell lines and tissues and this is related to
promoter hypermethylation since PTRF was successfully
restored through 5-AZA treatment [43].
Summary of epigenetics and caveolae related genes
There is growing evidence of a role of epigenetic mecha-
nisms in regulating CAV1, particularly in cancer (Table 1).
These effects appear to be cell type specific and different
epigenetic mechanisms may be involved in cells from dif-
ferent tissues. There is still limited knowledge on how epi-
genetics may regulate other caveolae related genes (CAV2,
CAV3 and PTRF).
Evidence of microRNA regulation of CAV1, CAV2 and PTRF
MicroRNAs (miRNAs) are able to regulate target tran-
scription and hence protein expression through binding
to the 3′-untranslated region of the matching target
mRNA [81, 82]. These small nucleotides have been re-
ported to be widely involved in physiological and patho-
physiological processes such as apoptosis [83], cellular
differentiation [84] and oncogenesis [85].
miRNAs have been shown to act as both tumor pro-
moters and suppressors. Evidence suggests that miRNA-
133a may act as an upstream regulator of CAV1 expression
in head and neck squamous cell carcinoma (HNCC) as the
expression of miRNA-133a is down-regulated while CAV1
is up-regulated in HNCC [86]. Luciferase reporter assays
showed that miRNA-133a interacts directly with CAV1
mRNA and transfection with a mirRNA-133a mimic results
in down-regulated CAV1 expression [86].
In vivo, a diet high in potassium results in increased ex-
pression of renal outer medullary potassium (ROMK)
channels, an effect thought to be mediated by up-
regulation of miRNA-802 [87]. The 3′-untranslated region
(UTR) of CAV1 contains sequences that allow direct inter-
action with miRNA-802. CAV1 inhibits ROMK channel
activity by interacting with the N-terminus of ROMK
channels [87]. When potassium increases, up-regulation
of miRNA-802 occurs which down-regulates CAV1’s ex-
pression by binding to the 3′UTR of CAV1. As CAV1 is
able to interact with the N-terminus of the ROMK chan-
nels (to down-regulate its expression) down-regulation of
CAV1 by miRNA-802 results in up-regulation of the
ROMK channels (Fig. 3) [87].
In obese mice, miRNA-103 and 107 are up-regulated
and may contribute to impaired glucose homeostasis
[88]. Knocking down both miRNAs results in an im-
proved response to insulin and glucose homeostasis [88].
CAV1 regulates insulin signaling [89] and CAV1 is re-
ported to be a target for both miRNA-103 and 107 [88].
Knocking down both miRNAs results in up-regulation
of CAV1 [88] and a stabilization of insulin receptors and
a responsive insulin signaling mechanism [88]. The find-
ings suggest the potential use of miRNA-103 and 107 as
therapeutic targets in treating diabetes and obesity.
CAV1 has been shown to be a direct target for
miRNA-199a-5p in the context of tissue fibrosis of sev-
eral organs (liver, kidney, lungs) [90]. Up-regulation of
miRNA-199a-5p in these tissues results in down-
regulation of CAV1 [90]. Interestingly, TGF-β, a factor
involved in fibrosis, induces the expression of miRNA-
199a-5p, which in turn causes the down-regulation of
CAV1 in these tissues [90]. In porcine adipocytes, there
is a high expression of miRNA-199a-5p [91]. Over-
expression of miRNA-199a-5p increases proliferation of
pre-adipocytes and inhibits the deposition of lipid in adi-
pocytes [91]. CAV1 has been shown to be involved in
lipogenesis [92, 17] and potentially miRNA-199a-5p may
play a role in controlling proliferation of adipocytes,
partly through regulating the expression of CAV1.
In porcine kidney epithelial (PK15) cells, miRNA-124
has been shown to directly interact with CAV1. In these
cells over-expression of miRNA-124 reduces CAV1 ex-
pression at both mRNA and protein levels, thus redu-
cing caveolae density and is associated with reduction in
pathogen uptake [93]. Therefore, expression of miRNA-
124 is proposed to be an important event that inhibits
invasion of pathogens in the kidney through down-
regulation of CAV1, and hence caveolae [93].
Docosahexaenoic acid (DHA) has been reported to
modulate the transcriptome of miRNAs in lipid metabolism
[94]. Exposure to DHA significantly increases the expres-
sion of miRNA-192 in enterocytes and CAV1 is predicted
to be a target for miRNA-192. Over-expression of miRNA-
192, results in reduced CAV1 expression [94]. However, the
biological significance of this relationship is not yet known.
Expression of miRNA-199a-3p has been reported to
be critical in promoting proliferation and survival of
endothelial and breast cancer cells. CAV2 has been
shown to be a target of miRNA-199a-3p [95] with over-
expression of CAV2 inhibiting the effect exerted by
miRNA-199a-3p in promoting proliferation, survival
and sensitivity of cancer cells to anticancer drugs [95].
The interaction between miRNA-199a-3p and CAV2
may provide an interesting target for intervention in
cancer.
Loss of miRNA-218 and up-regulation of CAV2 have
been observed in renal cell carcinoma (RCC) [96]. Over-
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expression of miRNA-218 and knocking down CAV2
significantly inhibits cellular proliferation, migration and
invasion of RCC [96]. Gene expression studies reveal
CAV2 to be regulated by miRNA-218. It has been sug-
gested that miRNA-218 acts as tumor suppressor by
regulating CAV2, possibly through the focal adhesion
pathway in RCC [96].
Interestingly, it has been shown that intestinal Sal-
monella infection is associated with miRNA-29a and
CAV2. CAV2 has been shown to be a direct target for
miRNA-29a [97]. Infection with Salmonella causes up-
regulation of miRNA-29a, which in turn results in
down-regulation of CAV2 and this is associated with
reduced proliferation of intestinal epithelial cells and
increased bacterial uptake in the intestinal epithelial
cells [97]. Further, over-expression of CAV2 or inhibition of
miRNA-29a leads to activation of CDC24 (an important
molecule that promotes the uptake of Salmonella into
cells), suggesting a possible mechanistic pathway for
Salmonella infection [97].
To date, there are no findings that describe a rela-
tionship between miRNA and PTRF. However, a recent
study suggests that expression of PTRF may modulate
the content of miRNA in extracellular vesicles secreted
from prostate cancer cells [98].
Summary of miRNA and caveolae related genes
The discovery and identification of miRNAs is beginning to
provide understanding of the upstream regulatory mecha-
nisms that regulate the expression of caveolae related genes.
Some evidence is available for a relationship between
miRNA and CAV1 and CAV2 (Table 2). However, the lack
of the knowledge between miRNA and other caveolae re-
lated genes warrants further investigation.
Perspective
Evidence suggests that environment and lifestyle fac-
tors may alter the epigenetic and miRNA profile in
humans and contribute to disease [99]. As discussed
above, caveolae related genes have been shown to play
a role in the pathophysiology of various disease states,
especially cancer. Although there is no evidence yet
available that environmental changes or diets affect
caveolae related genes epigenetically, growing evi-
dence suggests that diet could affect the expression of
miRNAs which will then affect the expression of cave-
olae related genes. Furthermore, it would be interest-
ing to investigate the downstream effects of epigenetic
changes to cellular physiology and pathophysiology.
Currently, limited evidence is available on this aspect
as most of the studies focus on the interaction of
Fig. 3 The role of dietary potassium in regulating miRNA-802 and CAV1 expression in the kidney. A diet high in potassium results in up-regulation of
miRNA-802 which down-regulates CAV1’s expression by binding to 3′UTR of CAV1. Interaction of CAV1 with the N-terminus of the ROMK
channels down-regulates these ion channels in the distal nephron, down-regulation of CAV1 results in up-regulation of the ROMK channels
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epigenetic changes to a particular caveolae related
gene but not the downstream effects (eg: changes in
cellular signaling mechanisms).
The involvement of mutations of the caveolae related
genes may also contribute to changes in cellular physi-
ology and pathophysiology. Mutations of CAV1 and
PTRF have been shown to be involved in congenital
lipodystrophy [100, 101]. As yet there is no evidence
available that epigenetic changes in expression of these
genes causes lipodystrophic effects, this may suggest
that epigenetic changes and mutations of caveolae re-
lated genes may predispose to different disease condi-
tions through these two different pathways. Currently
there are limited data concerning genetic mutations of
CAV2 or other caveolae associated genes.
Potentially, changes in the epigenetic status of caveo-
lae related genes could be developed as a biomarker for
diseases, in particular cancers. This could have several
advantages. Firstly, DNA is more stable than RNA and
secondly there are difficulties in differentiating between
RNA from normal and tumor cells, meaning that there
are advantages in using DNA as a biomarker over RNA
[102, 103]. Furthermore, DNA promoter hypermethyla-
tion occurs uniquely in the CpG rich area in the pro-
moter whereas genetic mutations can occur randomly
within the coding and non-coding region, and pro-
moter hypermethylation is an all-or-none event that
can be detected easily with a single pair of primers.
Lastly, minimally invasive methods can be used to col-
lect samples (for example urine and plasma) that can
then be used to detect epigenetic changes [104, 103].
Potentially, caveolae related genes that are silenced
through epigenetic mechanisms may be a useful bio-
marker for diagnostic purposes in the future.
miRNA has been reported to be dysregulated in a var-
iety of disease conditions. Even though the use of siRNA
as a therapeutic target is being clinically trialed, the use
of siRNA as a therapeutic target still poses some chal-
lenges. The high specificity, low toxicity, unique biogen-
esis and mechanism of action and the multiple targeting
ability of miRNA provide advantages over siRNA. With
the recognition of miRNA-caveolae related gene path-
ways in various disease states, miRNA may potentially
be a useful tool for gene intervention. Nevertheless, a
single miRNA is predicted to be able to bind to several
hundreds of different mRNA [105]. Therefore, should a
potential miRNA be developed as a therapeutic target, it
would need to be targeted to a specific tissue to avoid
unwanted effects which may occur in other tissues in
the body. Thus, with the emerging knowledge of the role
of miRNA in regulating caveolae related genes, modulat-
ing the expression of these key miRNAs could be a use-
ful therapeutic tool, as caveolae related genes have been
described to play important roles in health and disease.
Conclusion
Caveolae related genes have been shown to play important
roles in health and disease. Apart from genetic mutations,
growing evidence suggests that epigenetic mechanisms may
provide an upstream regulatory switch to control the ex-
pression of caveolae related genes hence contributing to
disease conditions. Potentially, these two events may occur
concurrently or exclusively to promote disease progression.
Identification of epigenetic modifications may open new
doors in biomarker and therapeutic target development to
complement the current options that have been developed
for genetic mutations. Much of the current evidence is fo-
cused on the changes in CAV1 expression by methylation,
Table 2 Relationship between miRNA and CAV1 and CAV2 in health and disease
miRNA Target caveolae
related gene
Changes observed and involvement in health and diseases
miRNA-133a CAV1 miRNA-133a is up-regulated in head and neck squamous cell carcinoma and down-regulates
CAV1 [86]
miRNA-802 CAV1 miRNA-802 is increased and up-regulates potassium channel expression in kidney by down-regulating
CAV1 [87]
miRNA-103 CAV1 miRNA-103 is up-regulated in obese animals and associated with impaired glucose homeostasis
by down-regulating CAV1 [88]
miRNA-107 CAV1 miRNA-107 is up-regulated in obese animals and associated with impaired glucose homeostasis
down-regulating CAV1 [88]
miRNA-199a-5p CAV1 miRNA-199a-5p is over-expressed in tissue fibrosis and pre-adipocytes, affects tissue fibrosis and
proliferation of pre-adipocytes [91, 90]
miRNA-124 CAV1 miRNA-124 down-regulates CAV1 and caveolae to prevent uptake of pathogens in kidney cells [93]
miRNA-192 CAV1 Exposure to DHA up-regulates miRNA-192 and down-regulates CAV1 [94]
miRNA-199a-3p CAV2 miRNA-199a-3p is up-regulated in breast cancer and down-regulates CAV2 [95]
miRNA-218 CAV2 miRNA-128 is down-regulated in renal cell carcinoma and up-regulates CAV2 [96]
miRNA-29a CAV2 miRNA-29a is up-regulated following Salmonella infection and down-regulates CAV2 [97]
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acetylation and miRNA and less is known for CAV2 and
PTRF. Therefore, further studies are required to investigate
whether altering the epigenetic state of these caveolae re-
lated genes can affect disease progression and if they can be
used as biomarkers for disease identification.
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